ClinicalTrials.gg
RecruitingNCT05911529TRACK-MIUpdated Nov 10, 2026

Tracking the Linguistic Signatures of Motivational Interviewing in Acute Psychosis

An interventional study of Motivational Interviewing and Psychoeducation in Psychosis and Schizophrenia, sponsored by Psychiatric University Hospital, Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Psychiatric University Hospital, Zurich · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Nov 10, 2026Now RecruitingPrimary completion moved+9 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Psychotic Disorders with a site in Switzerland — 10 open to participants now, 11 under way, 3 of them phase 3. Psychotic Disorders · Switzerland.

Planned enrollment
8th of 20
128 · median 100
Started
2023
with 1 other
No phase
13 of 25
6 open now
Primary completion
2027-10
later than 5 of 10 live
Registered
16th of 25
by date
Lead sponsor
3 of 25
Psychiatric University Hospital, Zurich

Among the 25 studies in Psychotic Disorders with a site in Switzerland, this one is the 8th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 16th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

10 of the 25 studies in Psychotic Disorders with a site in Switzerland are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Psychotic Disorders with a site in Switzerland, or all of them as a file.
02

Study summary

Psychotic disorders are associated with high levels of distress, limitations in quality of life, and a high risk of chronification for those affected. The treatment guidelines recommend combining the pharmacological treatment with psychotherapeutic methods, starting already in the acute phase. At the same time, there is little research evidence on which mechanisms of psychotherapy are most effective and best feasible for the acute setting. Therefore, the aim is to run a pilot study to test specific psychotherapeutic interventions for patients with psychosis on acute psychiatric wards.

The method of "Motivational Interviewing" is a well-known and established interviewing technique, which originally comes from the treatment of addictive disorders. In this study, it is used to strengthen the therapeutic alliance between patient and practitioner already in the acute phase of the disease, to increase adherence, and thus to achieve the overall goal of better integrating patients with pronounced positive symptoms into treatment. This appears to be extremely important, as non-adherence represents one of the greatest risks for chronification of the disease. The intervention will subsequently be evaluated in comparison to "treatment as usual".

Read the detailed description

Psychotic disorders are among the top ten causes of long-term disability and have a high chronicity potential and a high risk of invalidity. One-fifth of all patients with schizophrenia suffer from chronic symptoms and impairments, and the disease is associated with low long-term work performance, a high degree of all mental health care resources and high socioeconomic costs. These findings demonstrate the importance of sufficient treatment for psychotic disorders and, most importantly, point to a need for research so that more effective treatments can be developed in the future.

In the recent decade, various psychotherapeutic programs with cognitive-behavioral background have been developed for patients with psychosis, and their efficacy has been investigated. Meta-analyses have shown superiority of cognitive-behavioral therapy for psychosis over standard treatment, both in combination with antipsychotic medication and without. Many of the psychological approaches have focused primarily on treating the deficits associated with psychosis, as for example cognitive remediation or social skills training. However, these methods are not feasible in the acute setting and there are only a few psychotherapeutic instruments that can be used within a short period of time for inpatient treatment.

The guidelines for the treatment of schizophrenia recommend a combination of antipsychotic medication and psychosis-specific cognitive behavioral therapy. This includes all stages of the illness, also in the acute phase. The Swiss Society for Psychiatry and Psychotherapy (SGPP) has stated in its treatment guidelines for schizophrenia that "our group recommends a structured psychotherapeutic approach even in the acute phase of the disease. The best evidence currently exists for cognitive-behavioral approaches, […]. In any case, the psychotherapeutic procedure must be adapted to the circumstances of the acute phase and there is an urgent need for research on how this can be arranged in the setting of an acute ward.". Despite this explicit recommendation, to our knowledge there have been no studies that have systematically investigated this in the acute setting and results of which could therefore inform future treatment recommendations. As proposed by the SGPP, the aim is to systematically test and evaluate psychotherapeutic interventions in the setting of an acute care unit in an initial pilot trial.

Therapeutic alliance during the acute phase of psychotic illness is one of the most pressing obstacles for successful long term recovery. In order for patients to accept much-needed medication and psychosocial therapy and not drop out prematurely, intrinsic motivation to adhere to therapy is crucial. Motivational Interviewing is a method, that has been developed and evaluated over the last three decades and that shows promising results, not only for patients with addiction but also for other patients who struggle with compliance and ambivalence towards treatment and change of behavior.

It is well known from clinical experience that patients are offered psychotherapy only late during the course of hospitalizations and not when it is highly needed - during the acute phase of their illness. Accordingly, there is a clear gap in the literature as to which interventions are particularly useful in this challenging yet crucial phase of the illness.

03

Conditions studied

  • Psychosis
  • Schizophrenia

Keywords

  • Psychosis
  • Motivational Interviewing
  • Psychotherapy for psychosis
  • Adherence to treatment
  • Therapeutic alliance
  • Acute phase
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • Male and female patients from inpatient units of the Psychiatric University Hospital of Zurich
  • ICD-10 diagnosis of a mental disorder with psychotic symptoms, including schizophrenia, schizotypal and delusional disorders (F20-F29), affective disorders with psychotic features (F30.2, F31.2, F31.5, F32.3, F33.3) and substance-induced psychotic disorders (F1x.5)
  • Fluent in German and able to understand the instructions

Exclusion criteria

Exclusion Criteria:

  • Organic schizophrenia-like disorder (ICD: F0.6)
  • Drug or alcohol abuse during treatment
  • Previous enrolment in the current study
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • During study: Complete stop of taking antipsychotic medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Motivational Interviewing Group

    Patients will receive three sessions of Motivational Interviewing within two weeks.

    Behavioral: Motivational Interviewing

  • Active comparator
    Control Group

    Patients in the control group receive three sessions of psychoeducation within two weeks.

    Behavioral: Psychoeducation

Interventions

  • BehavioralMotivational Interviewing

    In our study intervention, patients should receive three session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.

  • BehavioralPsychoeducation

    In the control intervention patients should also be given three sessions, in which no MI techniques take place. They will be carried out in the form of psychoeducational interventions, which are part of a standard treatment program for patients with schizophrenia during the acute and post-acute phases. Psychoeducation aims to inform patients about their illness and its treatment, enhancing both the understanding and the personally responsible handling of the illness and supporting those afflicted in coping with the disorder. Since we want to check whether the patients really benefit from the specific intervention rather than from receiving additional contact time, the patient in the control group will also be given three sessions. It is known that psychoeducation can have a positive effect on treatment out come by reducing relapse rate and the frequency of rehospitalizations, improving treatment ad herence, and shortening the length of inpatient hospital stays.

06

What researchers measure

Primary outcomes

  1. Change from first session in Therapeutic Alliance on the Scale to Assess Therapeutic Relationship

    The therapeutic relationship will be evaluated with the german version of the Scale to Assess Therapeutic Relationship (STAR). The patient (STAR-P) and clinician scales (STAR-C) each have 12 items comprising three subscales: positive collaboration and posi-tive clinician input in both versions, non-supportive clinician input in the patient version, and emotional difficulties in the clinician version.

    Time frame: First session and week 2 (or after 3 sessions of psychotherapeutic intervention)

  2. Change from Baseline in Treatment Adherence on the electronic patient records

    Adherence to medication and therapy will be assessed using the electronic patient records before and after the study intervention or control intervention.

    Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)

Secondary outcomes

  1. Change from Baseline in Symptom Severity measured with the Positive and Negative Syndrome Scale

    Psychotic symptoms are assessed with the Positive and Negative Syndrome Scale (PANSS). This is a structured interview, which consists of four scales measuring positive and negative syndromes of schizophrenia, their differential, and general severity of illness.

    Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)

  2. Change from Baseline in Motivation for psychotherapy in the Questionnaire to measure the motivation for psychotherapy

    Motivation for psychotherapy will be measured with the german version of the Questionnaire to measure the motivation for psychotherapy, a 4-point Likert-scale with 39 items.

    Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)

  3. Change from Baseline in readinesss to change using Questionnaire for Assessing Readiness for Change (FEVER)

    Stages of change will be assessed using the German version of the University of Rhode Is land Change Assessment (URICA), namely the "Fragebogen zur Erfassung der Veränderungsbereitschaft" (FEVER). The instrument assesses temporal motivational processes of behavioral change and comprises four sub scales: precontemplation, contemplation, action, and maintenance. In the German adapta tion, the original 32-item version was reduced to 24 items by removing the eight items of the maintenance subscale. As the maintenance phase of the German questionnaire has not been validated, it will additionally be explored using four qualitative questions. All items are rated on a 5-point Likert scale. All subscales demonstrated good reliability and validity.

    Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)

  4. Change from Baseline in levels of risk to self or others measured with Short-Term Assessment of Risk and Treatability (START)

    Levels of risk to self or others will be evaluated using the Short-Term Assessment of Risk and Treatability (START), a structured professional judgement instrument assessing multiple risk estimates relevant to acute psychiatric care. The instrument comprises 20 items that are evaluated in terms of both vulnerabilities (risk factors) and strengths (protective factors). Each item is rated separately on the vulnerability and strength scales using a 3-point Likert scale ranging from 0 (no/minimal) to 2 (high). Based on these ratings, structured risk estimates are provided across seven domains: violence, suicide, self-harm, substance abuse, unauthorized leave, self neglect, and victimization. It has demonstrated high interrater reliability, high internal consistency, convergent validity with other risk measures, strong predictive validity for various aggressive outcomes, and good predictive validity for self-harm.

    Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)

  5. Duration of involuntary admission

    The duration of involuntary admission will be assessed using electronic patient records.

    Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)

  6. Rehospitalisation

    The occurrence of rehospitalisation will be assessed using electronic patient records.

    Time frame: Within 6 months after discharge

  7. Communication patterns in dyadic patient clinician conversations

    The communication patterns in dyadic patient clinician conversations assessed using computational linguistic analyses of speech data collected during the trial.

    Time frame: During all three patient-clinician consultations conducted within one week

07

Study locations

1 of 1 sites recruiting
  • Psychiatric University Hospital Zurich
    Zurich, Canton of Zurich 8032, Switzerland
    Recruiting
    • Philipp Homan, Prof. · Contactphilipp.homan@pukzh.ch · +41 58 384 26 52
    • Philipp Homan, Prof. · Principal investigator
    • Rahel Horisberger, Dr.phil. · Sub investigator
08

References and documents

Publications

  • McGuire-Snieckus R, McCabe R, Catty J, Hansson L, Priebe S. A new scale to assess the therapeutic relationship in community mental health care: STAR. Psychol Med. 2007 Jan;37(1):85-95. doi: 10.1017/S0033291706009299. Epub 2006 Nov 9. PubMed 17094819 ↗
  • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261. PubMed 3616518 ↗
  • Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res. 2008 Mar;100(1-3):60-9. doi: 10.1016/j.schres.2007.12.470. Epub 2008 Feb 5. PubMed 18255269 ↗
  • Schwarzer, R., & Jerusalem, M. (1995). Generalized self-efficacy scale. In J. Weinman, S. Wright, & M. Johnston, Measures in health psychology: A user's portfolio causal and control beliefs. (pp. 35-37). NFER-NELSON.
  • Schulz, H., Nübling, R., & Rüddel, H. (1995). Entwicklung einer Kurzform eines Fragebogens zur Psychotherapiemotivation. Verhaltenstherapie, 5, 89-95.
  • Aghotor J, Pfueller U, Moritz S, Weisbrod M, Roesch-Ely D. Metacognitive training for patients with schizophrenia (MCT): feasibility and preliminary evidence for its efficacy. J Behav Ther Exp Psychiatry. 2010 Sep;41(3):207-11. doi: 10.1016/j.jbtep.2010.01.004. Epub 2010 Jan 28. PubMed 20167306 ↗
  • Bark N, Revheim N, Huq F, Khalderov V, Ganz ZW, Medalia A. The impact of cognitive remediation on psychiatric symptoms of schizophrenia. Schizophr Res. 2003 Oct 1;63(3):229-35. doi: 10.1016/s0920-9964(02)00374-2. PubMed 12957702 ↗
  • Cavelti M, Homan P, Vauth R. The impact of thought disorder on therapeutic alliance and personal recovery in schizophrenia and schizoaffective disorder: An exploratory study. Psychiatry Res. 2016 May 30;239:92-8. doi: 10.1016/j.psychres.2016.02.070. Epub 2016 Mar 2. PubMed 27137967 ↗
  • Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabe M, Giordano GM, Nielsen MO, Glenthoj LB, Pezzella P, Falkai P, Dollfus S, Gaebel W. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry. 2021 Mar 17;64(1):e21. doi: 10.1192/j.eurpsy.2021.13. PubMed 33726883 ↗
  • Grawe, K. (1995). Grundriss einer Allgemeinen Psychotherapie. Psychotherapeut, 40, 130-145.
  • Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, O'Donovan M, Correll CU, Kane JM, van Os J, Insel TR. Schizophrenia. Nat Rev Dis Primers. 2015 Nov 12;1:15067. doi: 10.1038/nrdp.2015.67. PubMed 27189524 ↗
  • Kaiser, S., Berger, G., Conus, P., Kawohl, W., Müller, T. J., Schimmelmann, B. G., Traber, R., Trächsel, N., Vauth, R., & Seifritz, E. (2016). SGPP Behandlungsempfehlungen Schizophrenie. Schweizerische Gesellschaft für Psychiatrie und Psychotherapie.
  • Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014 Mar;29(2):63-76. doi: 10.1097/YIC.0b013e32836508e6. PubMed 23995856 ↗
  • Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ. 2014 Feb 12;348:g1173. doi: 10.1136/bmj.g1173. No abstract available. PubMed 24523363 ↗
  • Lincoln, T. M., & Pedersen, A. (2019). An Overview of the Evidence for Psychological Interventions for Psychosis: Results From Meta-Analyses. Clinical Psychology in Europe, 1(1), 1-23. https://doi.org/10.32872/cpe.v1i1.31407
  • Mehl, S., & Lincoln, T. (2014). Therapie-Tools Psychose. Beltz.
  • Morrison AP, Hutton P, Wardle M, Spencer H, Barratt S, Brabban A, Callcott P, Christodoulides T, Dudley R, French P, Lumley V, Tai SJ, Turkington D. Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. Psychol Med. 2012 May;42(5):1049-56. doi: 10.1017/S0033291711001899. Epub 2011 Sep 14. PubMed 21914252 ↗
  • Morrison AP, Turkington D, Pyle M, Spencer H, Brabban A, Dunn G, Christodoulides T, Dudley R, Chapman N, Callcott P, Grace T, Lumley V, Drage L, Tully S, Irving K, Cummings A, Byrne R, Davies LM, Hutton P. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet. 2014 Apr 19;383(9926):1395-403. doi: 10.1016/S0140-6736(13)62246-1. Epub 2014 Feb 6. PubMed 24508320 ↗
  • Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004 Jun 19;363(9426):2063-72. doi: 10.1016/S0140-6736(04)16458-1. PubMed 15207959 ↗
  • Murray, C. J. L., & Lopez, A. D. (1996). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020.
  • National Institute for Health and Clinical Excellence (2010). Schizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf
  • Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016 Jul 2;388(10039):86-97. doi: 10.1016/S0140-6736(15)01121-6. Epub 2016 Jan 15. PubMed 26777917 ↗
  • Puig O, Penades R, Baeza I, De la Serna E, Sanchez-Gistau V, Bernardo M, Castro-Fornieles J. Cognitive remediation therapy in adolescents with early-onset schizophrenia: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2014 Aug;53(8):859-68. doi: 10.1016/j.jaac.2014.05.012. Epub 2014 Jun 21. PubMed 25062593 ↗
  • Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012 May;137(1-3):147-50. doi: 10.1016/j.schres.2012.01.015. Epub 2012 Feb 6. PubMed 22316568 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Oct 2027, 55 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 55 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2023 → Oct 2027 and completion Dec 2023 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
Jun 22, 2023
StartActual
Mar 15, 2023
Primary completionEst.
Oct 31, 2027was Dec 2023
CompletionEst.
Oct 31, 2027was Dec 2023
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Nov 10, 2026
Sites
1 site added, 1 site removed
Show site
  • Psychiatric University Hospital Zurich · Zurich, Switzerland
Show 1 removed
  • Psychiatric University Hospital Zurich · Zürich, Switzerland
Nov 10, 2026
Primary completion
Dec 31, 2023→Oct 31, 2027
Nov 10, 2026
Study completion
Dec 31, 2023→Oct 31, 2027
Nov 10, 2026
Enrollment
28 (actual)→128 (estimated)
Nov 10, 2026
Eligibility
1 inclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedICD-10 diagnosis of psychosis (F2.x)
  • AddedICD-10 diagnosis of a mental disorder with psychotic symptoms, including schizophrenia, schizotypal and delusional disorders (F20-F29), affective disorders with psychotic features (F30.2, F31.2, F31.5, F32.3, F33.3) and substance-induced psychotic disorders (F1x.5)
Nov 10, 2026
Interventions
Added Behavioral: Psychoeducation; removed Behavioral: Supportive conversations
Nov 10, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange from Baselinefirst session in Therapeutic Alliance on the Scale to Assess Therapeutic RelationshipTime frame: Baseline and week 3 (or after 4 sessions of psychotherapeutic intervention) → First session and week 2 (or after 3 sessions of psychotherapeutic intervention)
  • EditedChange from Baseline in Treatment Adherence on the Brief Adherence Rating Scaleelectronic patient recordsTime frame: Baseline and week 3 (or after 4 sessions of psychotherapeutic intervention) → Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
Nov 10, 2026
Secondary outcomes
2 time frame changed, 5 added, 1 removed
What changed in the outcomes
  • AddedChange from Baseline in readinesss to change using Questionnaire for Assessing Readiness for Change (FEVER)Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
  • AddedChange from Baseline in levels of risk to self or others measured with Short-Term Assessment of Risk and Treatability (START)Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
  • AddedDuration of involuntary admissionTime frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
  • AddedRehospitalisationTime frame: Within 6 months after discharge
  • AddedCommunication patterns in dyadic patient clinician conversationsTime frame: During all three patient-clinician consultations conducted within one week
  • RemovedChange from Baseline in Self-Efficacy on the General Self-Efficacy ScaleTime frame: Baseline and week 3 (or after 4 sessions of psychotherapeutic intervention)
  • Time frameChange from Baseline in Symptom Severity measured with the Positive and Negative Syndrome ScaleBaseline and week 3 (or after 4 sessions of psychotherapeutic intervention) → Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
  • Time frameChange from Baseline in Motivation for psychotherapy in the Questionnaire to measure the motivation for psychotherapyBaseline and week 3 (or after 4 sessions of psychotherapeutic intervention) → Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
Nov 10, 2026
Contact
Study contact now listed: added r•••@pukzh.ch · •••2652; added j•••@pukzh.ch · •••2423. See the current contact
Nov 10, 2026
Title
Motivational Interviewing for Patients With Acute Psychosis→Tracking the Linguistic Signatures of Motivational Interviewing in Acute Psychosis
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Completed→Recruiting
    1 site added, 1 site removed
    Show site
    • Psychiatric University Hospital Zurich · Zurich, Switzerland
    Show 1 removed
    • Psychiatric University Hospital Zurich · Zürich, Switzerland
    Primary completion Dec 31, 2023→Oct 31, 2027
    Study completion Dec 31, 2023→Oct 31, 2027
    Enrollment 28 (actual)→128 (estimated)
    Eligibility 1 inclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedICD-10 diagnosis of psychosis (F2.x)
    • AddedICD-10 diagnosis of a mental disorder with psychotic symptoms, including schizophrenia, schizotypal and delusional disorders (F20-F29), affective disorders with psychotic features (F30.2, F31.2, F31.5, F32.3, F33.3) and substance-induced psychotic disorders (F1x.5)
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange from Baselinefirst session in Therapeutic Alliance on the Scale to Assess Therapeutic RelationshipTime frame: Baseline and week 3 (or after 4 sessions of psychotherapeutic intervention) → First session and week 2 (or after 3 sessions of psychotherapeutic intervention)
    • EditedChange from Baseline in Treatment Adherence on the Brief Adherence Rating Scaleelectronic patient recordsTime frame: Baseline and week 3 (or after 4 sessions of psychotherapeutic intervention) → Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
    Secondary outcomes 2 time frame changed, 5 added, 1 removed
    What changed in the outcomes
    • AddedChange from Baseline in readinesss to change using Questionnaire for Assessing Readiness for Change (FEVER)Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
    • AddedChange from Baseline in levels of risk to self or others measured with Short-Term Assessment of Risk and Treatability (START)Time frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
    • AddedDuration of involuntary admissionTime frame: Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
    • AddedRehospitalisationTime frame: Within 6 months after discharge
    • AddedCommunication patterns in dyadic patient clinician conversationsTime frame: During all three patient-clinician consultations conducted within one week
    • RemovedChange from Baseline in Self-Efficacy on the General Self-Efficacy ScaleTime frame: Baseline and week 3 (or after 4 sessions of psychotherapeutic intervention)
    • Time frameChange from Baseline in Symptom Severity measured with the Positive and Negative Syndrome ScaleBaseline and week 3 (or after 4 sessions of psychotherapeutic intervention) → Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
    • Time frameChange from Baseline in Motivation for psychotherapy in the Questionnaire to measure the motivation for psychotherapyBaseline and week 3 (or after 4 sessions of psychotherapeutic intervention) → Baseline and week 2 (or after 3 sessions of psychotherapeutic intervention)
    Interventions Added Behavioral: Psychoeducation; removed Behavioral: Supportive conversations
    Contact Study contact now listed: added r•••@pukzh.ch · •••2652; added j•••@pukzh.ch · •••2423. See the current contact
    Title Motivational Interviewing for Patients With Acute Psychosis→Tracking the Linguistic Signatures of Motivational Interviewing in Acute Psychosis
    + 3 other changes: verification date, description and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05911529
Lead sponsor
Psychiatric University Hospital, Zurich
Responsible party
Rahel Horisberger (Clinical psychologist, PhD, Psychiatric University Hospital, Zurich) — Principal investigator
First posted
Jun 22, 2023
Start date
Mar 15, 2023
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Rahel Horisberger, Dr.phil.
Contact
rahel.horisberger@pukzh.ch
+41 58 384 26 52
Janani Panchalingam, M.Sc.
Contact
janani.panchalingam@pukzh.ch
+41 58 384 24 23
Philipp Homan, Prof.
principal investigator · University of Zurich

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion